MedTrace Logo

Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies

NCT05237206 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2025-09-18

Study results available
· View outcomes & findings →

Summary

This Phase 1, first-in-human (FIH), open-label study is designed to assess the safety, tolerability, and preliminary clinical efficacy of repeated intravenous (IV) infusions of SUPLEXA monotherapy in subjects with measurable metastatic solid tumours and haematologic malignancies

Conditions

Interventions

BIOLOGICAL

SUPLEXA

PBMC-derived autologous cellular therapy derived through an ex vivo activation procedure, resulting in a cell mixture comprised predominantly of NK, NK-T, and T cells stored in cryogenic media.

Sponsors & Collaborators

  • Alloplex Biotherapeutics Inc

    lead INDUSTRY

Principal Investigators

  • Rohit Joshi, MD · Cancer Research South Australia (CRSA)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-28
Primary Completion
2024-07-23
Completion
2024-07-23

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05237206 on ClinicalTrials.gov